2,144,633 Shares in BioAge Labs, Inc. $BIOA Bought by Jupiter Topco LLC

Jupiter Topco LLC acquired a new stake in shares of BioAge Labs, Inc. (NASDAQ:BIOA) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,144,633 shares of the company’s stock, valued at approximately $52,597,000. Jupiter Topco LLC owned about 4.67% of BioAge Labs as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of BIOA. CWM LLC grew its stake in shares of BioAge Labs by 39.9% during the 4th quarter. CWM LLC now owns 3,693 shares of the company’s stock valued at $49,000 after purchasing an additional 1,053 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of BioAge Labs by 24.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,808 shares of the company’s stock valued at $196,000 after purchasing an additional 2,917 shares during the last quarter. Barclays PLC lifted its stake in shares of BioAge Labs by 9.3% in the 4th quarter. Barclays PLC now owns 37,780 shares of the company’s stock worth $500,000 after purchasing an additional 3,222 shares during the period. Legal & General Group Plc bought a new position in shares of BioAge Labs in the 2nd quarter worth approximately $84,000. Finally, Bank of America Corp DE boosted its holdings in shares of BioAge Labs by 46.3% in the third quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock worth $65,000 after buying an additional 3,517 shares during the last quarter.

BioAge Labs Price Performance

Shares of BIOA stock opened at $10.08 on Friday. The company has a market capitalization of $462.67 million, a price-to-earnings ratio of -4.24 and a beta of 0.93. BioAge Labs, Inc. has a one year low of $4.55 and a one year high of $25.95. The company’s fifty day moving average price is $18.03 and its 200-day moving average price is $18.25.

BioAge Labs (NASDAQ:BIOA) last issued its earnings results on Wednesday, August 5th. The company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.07. BioAge Labs had a negative net margin of 912.26% and a negative return on equity of 28.99%. The company had revenue of $2.45 million during the quarter. Equities research analysts expect that BioAge Labs, Inc. will post -2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Wall Street Zen cut shares of BioAge Labs from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. Roth Capital reiterated a “buy” rating and set a $25.00 price target on shares of BioAge Labs in a research note on Friday, July 31st. Jefferies Financial Group set a $21.00 price objective on shares of BioAge Labs in a research report on Friday, July 31st. Needham & Company LLC reduced their price objective on BioAge Labs from $50.00 to $35.00 and set a “buy” rating for the company in a research note on Friday, July 31st. Finally, BTIG Research reaffirmed a “buy” rating and issued a $40.00 target price on shares of BioAge Labs in a report on Monday, August 3rd. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.57.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.